Prior history of atrial fibrillation and arrhythmic outcomes: Data from the WEARIT-II prospective registry
- PMID: 38383981
- DOI: 10.1111/jce.16215
Prior history of atrial fibrillation and arrhythmic outcomes: Data from the WEARIT-II prospective registry
Abstract
Introduction: Wearable cardioverter defibrillator (WCD) is utilized in patients with assumed but not yet confirmed risk for sudden cardiac death (SCD). Many of these patients also present with atrial fibrillation (AF). However, the rate of WCD-detected ventricular or atrial arrhythmia events in this specific high-risk cohort is not well understood.
Methods: In WEARIT-II, the cumulative probability of any sustained or nonsustained VT/VF (WCD-treated and nontreated), and atrial/supraventricular arrhythmias during WCD use was assessed using the Kaplan-Meier method by prior AF, with comparisons by the log-rank test. The incidence of ventricular and atrial arrhythmia events were expressed as events per 100 patient-years, and were analyzed by prior AF using negative binomial regression.
Results: WEARIT-II enrolled 2000 patients, 557 (28%) of whom had AF before enrollment. Cumulative probability of any sustained or nonsustained WCD-detected VT/VF during WCD use was significantly higher among patients with a history of AF than without AF (6% vs. 3%, p = .001). Similarly, the recurrent rate of any sustained or nonsustained VT/VF was significantly higher in patients with prior AF versus no prior AF (131.5 events per 100 patient-years vs. 22.7 events per 100 patient-years, p = .001). Patients with prior AF also had a significantly higher burden of any WCD-detected atrial arrhythmias/SVT/inappropriate arrhythmias therapy (183.2 events per 100 patient-years vs. 74.8 events per 100 patient-years, p < .001).
Conclusion: Our results demonstrate that patients with a history of AF wearing the WCD for risk assessment have a higher incidence of ventricular arrhythmias that may facilitate the decision making for ICD implantation.
Keywords: atrial fibrillation; ventricular arrhythmias; wearable cardioverter defibrillator.
© 2024 Wiley Periodicals LLC.
References
REFERENCES
-
- Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877‐883.
-
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter‐defibrillator for congestive heart failure. N Engl J Med. 2005;352:225‐237.
-
- Piccini Sr. JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable cardioverter‐defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation. 2016;133:1715‐1727.
-
- Goldenberg I, Erath JW, Russo AM, et al. Sex differences in arrhythmic burden with the wearable cardioverter‐defibrillator. Heart Rhythm. 2021;18:404‐410.
-
- Bardai A, Blom MT, van Hoeijen DA, van Deutekom HWM, Brouwer HJ, Tan HL. Atrial fibrillation is an independent risk factor for ventricular fibrillation: a large‐scale population‐based case‐control study. Circ Arrhythm Electrophysiol. 2014;7:1033‐1039.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical